


**Product Name** : PF-00835231  
**Cat. No.** : PC-72752  
**CAS No.** : 870153-29-0  
**Molecular Formula** : C<sub>24</sub>H<sub>32</sub>N<sub>4</sub>O<sub>6</sub>  
**Molecular Weight** : 472.542  
**Target** : SARS-CoV-2 Inhibitors  
**Solubility** : 10 mM in DMSO



## Biological Activity

PF-00835231 (PF00835231) is a potent inhibitor of pan-coronavirus family **3CL pro** (IC<sub>50</sub>=0.27 nM, SARS CoV-2), with selectivity over human host protease targets.

PF-00835231 inhibits SARS CoV-1 3CL pro with IC<sub>50</sub> of 4 nM, displaying IC<sub>50</sub> values of >10 μM against many of the other proteases and possessing modest levels of inhibition of cathepsin B (IC<sub>50</sub> = 1.3 μM) and rhinovirus 3Cpro (IC<sub>50</sub> = 1.7 μM).

PF-00835231 demonstrated potent inhibitory activity against all tested coronavirus 3CLpro including members of alpha-coronaviruses (NL63-CoV, HCoV-229E, PEDV, FIPV), beta-coronaviruses (HKU4-CoV, HKU5-CoV, HKU9-CoV, MCoV, OC43-CoV, HKU1-CoV), and gamma-coronavirus (IBV-CoV), with K<sub>i</sub> values ranging from 30 pM to 4 nM.

PF-00835231 exhibited viral effect against SARS-CoV-2 in cell culture, also showed potential synergy with remdesivir in HeLa-ACE2 cells.

PF-00835231 demonstrated in vivo effect in mouse models of SARS-CoV and SARS-CoV-2 infection.

## References

de Vries M, et al. *J Virol*. 2021 Feb 23;95(10):e01819-20.

Liu C, et al. *Antiviral Res*. 2021 Mar;187:105020.

Hoffman RL, et al. *J Med Chem*. 2020 Nov 12;63(21):12725-12747.

Robert L Hoffman, et al. *J Med Chem*. 2020 Nov 12;63(21):12725-12747.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com